Recently, vaccines against the Wilms' Tumor antigen 1 (WT1) have been tested in cancer patients.
Introduction
The Wilms' Tumor antigen 1 (WT1) is an attractive target for immunotherapy of leukemia and solid tumors as it is expressed at high levels in many malignancies, while progenitor and stem cell populations express only low levels of the WT1 transcription factor (1) (2) (3) (4) (5) . In acute myeloid leukemia (AML), high WT1 levels are associated with poor prognosis, and the quantitative measurement of WT1 RNA transcripts is now widely accepted as a sensitive molecular marker for monitoring minimal residual disease in patients undergoing chemotherapy or transplantation (6).
In the past few years vaccination with WT1 peptides has been tested as a treatment option for various malignancies including myelodysplasia and leukemia. (7) (8). In these studies clinical responses were observed in 60-74% of evaluable patients (including stable disease and reduced expression of tumor markers), but correlation with the detection of immunological responses in peripheral blood was variable. Studies in breast cancer patients showed that WT1-specific T cells were undetectable in peripheral blood, although present in tumor-draining lymph nodes (9).
Therefore, failure to detect WT1-sepcific T cells in the blood of cancer patients might be due to selective migration to the site of tumor growth.
It is possible that low-level WT1 expression in normal progenitor cells may result in the central deletion of high avidity WT1-specific T cells or induce unresponsiveness by peripheral tolerance mechanisms. However, there is good evidence indicating that central and peripheral tolerance to WT1 is incomplete. Firstly, vaccination in humans can induce self-restricted WT1-specific T cell responses in some patients, although their frequency is generally low (10). In addition, WT1-specific T cells were detectable in leukemia patients after allogeneic stem cell transplantation and their detection correlated with low risk of leukemia relapse (11). Finally, WT1-specific T cells can be detected in the peripheral blood of healthy individuals (12-17).
It is currently unclear to what extent self antigen expression in normal tissue shapes the phenotype and functional activity of WT1-specific T cells. For example, recent studies examining the in vivo For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From generation of 'natural' memory phenotype T cells have suggested that self antigen might trigger naïve T cells to differentiate into memory phenotype cells (22) (23, 40) . In this study we designed murine model experiments to analyse the thymic development of HLA-A0201-restricted, WT1-specific T cells and to determine the phenotype and function of these cells in the periphery.
Previously, we have used the allo-restricted strategy to isolate HLA-A0201-restricted, pWT126-specific T cells from healthy individuals (18, 19) . High avidity T cell lines were established and used to isolate the genes encoding the alpha and beta chains of a pWT126-specific TCR.
Retroviral TCR gene transfer readily converted human peripheral blood T cells into high avidity, pWT126-specific CTL (20) , which were able to recognise and kill CD34+ cells of leukemia patients but not normal CD34+ haematopoietic progenitor/stem cells. Furthermore, adoptive therapy with TCR-gene transduced T cells resulted in the elimination of autologous leukemia cells in the xenogenic NOD/SCID model (21) .
In this study, we transferred the WT1-TCR gene into purified murine lineage-negative haematopoietic stem cells. Transplantation of the gene-modified stem cells into HLA-A0201 transgenic recipients allowed us to study the phenotype and function of TCR-expressing cells in the thymus and periphery. Surprisingly, WT1-specific T cells were not impaired by central or peripheral tolerance, but differentiated instead into memory phenotype T cells able to display antigen-specific effector function. Thus, self-specificity for a tumor-associated antigen can contribute to the establishment of natural memory phenotype T cells (22, 23) . The implications of these findings for WT1-based vaccination strategies are discussed.
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Material and Methods

Mice
C57BL/6 mice, were purchased from Charles Rivers (UK), or from the Comparative Biology Unit (CBU) of University College London, Royal Free Campus. HLA-A2Kb transgenic (A2Kb Tg) mice on a C57Bl/6 background were a kind gift from Theobald M (UMC, Utrecht, NL). C57Bl/6 CD45.1 and A2KbxCD45.1 Tg mice were bred and maintained in the CBU of University College London. All animals were housed in pathogen-free conditions in individually ventilated cages (IVCs) and were kept in accordance with the University and UK Home Office regulations. All procedures were performed aseptically and irradiated animals received 2.5% enrofloxacin (Baytril, Bayer) in their water 1 week prior to irradiation and for 2 weeks post. Donor mice were 7-10 weeks old at the time of bone marrow (BM) harvest. Recipient mice were 12 weeks old at transplant and received 9.4Gy irradiation in two divided doses at day -2 and day 0. Secondary adoptive transfer recipients were sublethally irradiated (5Gy), 4 hours before T cell transfer.
Lentiviral Vector Constructs
A pSIN second generation lentiviral vector, containing a spleen focus forming virus (SFFV) LTR promoter and the HIV-1 central polypurine tract cis-active element (cPPT) was modified for this study. Both the codon-optimised hybrid HLA-A*0201-restricted WT1-specific TCR and LMP2-specific TCR genes have been described before (21, 30) . The WT1-TCR utilises the Vβ2.1 and Vα1.5 TCR chains and is specific for the WT126 peptide, RMFPNAPYL. The LMP2-TCR utilises the Vβ13.1 and Vα3.1 TCR chains and is specific for the CLG peptide, CLGGLLTMV. The hybrid TCR sequences contain murine constant and human variable region sequences. An additional disulphide bond between the alpha and beta chains was created by the introduction of two additional cysteine residues in the alpha and beta chain constant regions. The genes for the TCR alpha and beta chains cloned into the lentiviral vector were separated by a porcine tsechovirus self-cleaving 2A sequence to optimise expression of both TCR alpha and beta chain genes. The leader sequence was derived from the pMP71 retroviral vector and the full length woodchuck hepatitis virus post-transcriptional regulatory element was truncated to prevent encoding of the oncogenic protein X (41). 
HSC isolation, infection and transfer
Whole BM was harvested from 7-10 week old donor mice (C57Bl/6 or A2Kb Tg as specified in each experiment). Briefly, femurs, tibias and pelvic bones were removed and the BM was harvested by flushing it with cold RPMI medium containing 1%P/S with a syringe equipped with a 25gauge needle. Uncommitted BM progenitors, highly enriched in HSCs, were negatively selected using either the Lineage cell depletion kit for mouse (Miltenyi Biotech), or the Haematopoietic Progenitor Enrichment kit (StemCell Technologies) following the manufacturers' protocols. The lineage negative selected cells (Lin-ve BM cells) were placed in culture at 1x10 6 cells/ml in StemSpan medium (StemCell Technologies) containing 1% P/S, 100ng/ml mSCF, 100ng/ml hFLT-3, 100ng/ml hIL-11 and 20ng/ml mIL-3. All cytokines were purchased from Peprotech. The Lin-ve Lin-ve BM cells/each by tail vein injections. Tail bleeds were performed at weeks 5, 7 and 9 posttransplant. Recipient mice were sacrificed 11 weeks post-transplant and thymus, spleen, LNs and BM were harvested for phenotypic analysis and functional characterisation of T cells.
Adoptive T cell transfer into secondary recipients
Lentiviral TCR-transduced C57BL/6 Lin-ve BM cells were transferred into lethally irradiated A2KbxCD45.1 Tg recipients as described above. 17 weeks post transplant the mice were sacrificed and their spleens were harvested. Untouched CD3 T cell selection was performed on splenocytes pooled from 5 primary recipients, using a mouse pan-T cell isolation kit (Miltenyi Biotech). 3x10 6 T cells were transferred to secondary A2KbxCD45.1 recipients that were sublethally irradiated (5Gy) 1 day prior to the transfer. Tail bleeds were performed at d9 and d28
post-adoptive transfer. On d69-70 in vivo cytotoxicity assays (see below) were performed.
Splenocytes from the secondary recipients were used in ex-vivo proliferation assays (see below).
Serial HSC transplants
BM cells from primary WT1-TCR HSC transplant recipients (A2KbxCD45.1 to A2Kb transplant)
were pooled together and then transferred into lethally irradiated (9.4Gy) C57BL/6 mice (5x10 
Antibodies and FACS analysis
The following fluorescently labelled anti-murine antibodies (BD Bioscience) were used in the study:
CD45.1 APC Cy7, CD3 APC, CD3 FITC CD4 FITC, CD8a PECy5, CD44 APC, CD62L FITC, B220
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From PECy5, CD11b APC, and streptavidin APC. Anti-human Vβ2.1 PE, Vβ2.1 biotin and Vβ13 were purchased from Immunotech. An LSR II cytometer (BD Bioscience) was used for Flow Cytometric analysis and data were analysed using FlowJo software (Tree Star).
In vivo cytotoxicity assays
Splenocytes from female A2Kb Tg mice were peptide loaded with 100μM of either relevant peptide 
Ex-vivo proliferation assays
Splenocytes from mice that had been transplanted with WT1 or LMP2-TCR-transduced HSCs, or mice that had received an adoptive transfer of T cells from primary transplant recipients, were labelled with 1.5μM CFSE as above and placed in culture at 1x10 6 cells/ml. Previous studies have shown that retroviral TCR gene transfer into haematopoietic stem cells can serve to analyse the development and function of antigen-specific T cells in the thymus and periphery (24, 25). In these studies, retroviral vectors were used to infect bulk bone marrow cells followed by transfer into myeloablated recipients. We found that lentiviral vectors efficiently transduced purified, lineage-negative stem cells that efficiently reconstituted conditioned recipients and developed into mature T cells. Hence, we assembled a lentiviral vector containing the HLA-A0201-restricted TCR specific for the WT1-derived peptide pWT126 ( Fig 1A) . The human constant regions of the TCR alpha and beta genes were replaced with murine sequences to facilitate expression in murine cells (26). The constant regions were further modified to encode a cysteine residue to improve the pairing of the introduced TCR alpha and beta chains ( Fig 1B) (27).
Haematopoietic stem cells were transduced with the WT1-TCR lentiviral construct prior to transplantation into myeloablated transgenic A2Kb mice (Fig 1D) . The transgenic mice expressed a hybrid HLA-A0201 molecules consisting of human alpha-1 and alpha-2 domains, which together form the peptide binding groove required for antigen presentation (Fig 1C) . The alpha-3 domain was of murine origin to facilitate appropriate interaction between murine CD8 co-receptors and the hybrid HLA molecule. Importantly, both human and murine WT1 proteins are highly conserved and the HLA-A0201 presented pWT126 peptide is identical between the two species. It has been demonstrated that murine cells expressing murine WT1 can generate the pWT126 for MHC presentation and T cell recognition (28). Further, the endogenous WT1 expression pattern in normal tissues is very similar in humans and mice (29). Thus, the HLA transgenic host provides an in vivo model to investigate how physiological WT1 expression affects the development and function of HLA-restricted, WT1-specific T cells.
WT1-specific T cells are selected in the thymus.
Purified lineage negative bone marrow stem cells from A2Kb transgenic mice were transduced with the lentiviral WT1-TCR vector. Using CD4/8 phenotyping and staining with anti-human Vβ antibodies we found expression of the WT1-TCR in immature double-negative thymocytes and also in the more mature double-positive population (Fig 2A) 
WT1-specific T cells persist in the periphery and differentiate into memory phenotype cells without vaccination.
Next we explored whether TCR-expressing cells were detectable in the periphery of transplanted mice (A2Kb→A2Kb). Mature T cells expressing the WT1-TCR were readily detectable in the spleen, lymph nodes and bone marrow ( Fig 3A) . As expected, the WT1-TCR was expressed in peripheral CD8+ T cells and not in CD4+ cells (Fig 3B) . Anti-CD3 antibodies were used to measure the level of TCR/CD3 complex expression in all T cells derived from the transplanted stem cell population. There was a substantial reduction in the level of CD3 expression in the WT1-TCRpositive T cells compared to the WT1-TCR-negative T cells (Fig 3C) . Low expression of the WT1-TCR could be due to the self-specificity of this TCR, or alternatively it could be due to low promoter activity of the lentiviral vector driving TCR expression. We therefore replaced the WT1-TCR variable gene segments in the lentiviral vector with the variable region gene segments of an HLA-A0201-restricted TCR specific for a non-self peptide derived from the Latent Membrane Protein 2 (LMP2) of Epstein Barr virus (30). Transplantation experiments with transduced stem cells indicated that mature T cells expressing the LMP2-TCR were readily detectable in the spleen, lymph nodes and bone marrow of transplanted mice ( Fig 3A) . As expected, LMP2-TCR expression was limited to CD8+ T cells and not seen in CD4+ T cells (Fig 3B) . Importantly, the level of CD3 expression in the LMP2-TCR-positive T cells was similar to that seen in control T cells expressing endogenous TCR (Fig 3C) . This indicated that the reduced level of TCR/CD3 expression was not caused by poor expression from the lentiviral vector, but was a feature of the self-reactive WT1-TCR and not of the non-self reactive LMP2-TCR.
In previous transgenic models the down-modulation of TCR and CD8 was described as an important mechanism of peripheral tolerance induction (31). Unexpectedly, TCR down-modulation in WT1-specific T cells was associated with an up-regulation of CD8 co-receptor expression ( Fig   3D) . The down-modulation of TCR and up-regulation of CD8 co-receptors was only seen in WT1-specific T cells and not in T cells specific for the non-self LMP2 antigen (Fig 3D) .
Differences in TCR and CD8 expression between WT1 and LMP2-specific T cells correlated with differences in their activation status. The expression of the CD44 activation marker in LMP2-specific (TCR +ve) T cells was similar to that seen in endogenous control (TCR -ve) T cells ( Fig   4A) . In contrast, a large proportion of the WT1-specific T cells expressed high levels of CD44 and CD62L, a phenotype normally associated with central memory T cells (Fig 4A) . recipients. In the transplanted mice, haematopoietic cells including professional APC were unable to present antigen to the HLA-A0201-restricted WT1-TCR. Analysis of WT1-specific T cells in these mice showed that the development of CD44 high CD62L high memory phenotype cells was not dependent upon antigen presentation by haematopoietic cells (Fig 4A, lower row) .
A more detailed analysis of the naïve (CD44 low CD62L high ), central memory (CD44 high CD62L high ) and effector memory (CD44 high CD62L ow ) T cell frequencies in mice expressing WT1-TCR or LMP2-TCR
showed that the WT1-TCR expressing population contained significantly less naïve phenotype T cells compared to LMP2-TCR expressing population (p < 0.001) (Fig 4B) . Within the WT1-specific T cells the TCR-low population contained primarily memory phenotype cells, while the TCR-high population contained both naïve and memory phenotype T cells (Fig 4C) .
Together, these observations suggested that naïve phenotype T cells differentiated into memory phenotype cells by a mechanism that involved TCR triggering, which resulted in TCR downmodulation and up-regulation of the CD44 activation marker. It is possible that the lymphopenic environment of transplanted mice facilitates the generation of WT1-specific memory T cells, although this environment does not promote LMP2-specific memory T cell development.
WT1-specific T cells display antigen-specific effector function without vaccination.
We explored whether WT1-specific T cells, and more specifically the memory phenotype T cells, were able to display antigen-specific effector function. In vivo cytotoxicity assays revealed strong antigen-specific killing activity in A2Kb mice transplanted with WT1-TCR transduced A2Kb stem cells or B6 stem cells (Fig 5A) . In contrast, no antigen-specific killing was observed in mice transplanted with LMP2-TCR transduced stem cells, although the number of peripheral T cells expressing the LMP2-TCR or WT1-TCR was similar (Fig 5A) . Ex vivo, the WT1-specific T cells isolated from both A2Kb→A2Kb and B6→A2Kb transplanted mice displayed antigen-specific proliferation (Fig 5B) , IL2 and IFN gamma production (Fig 5C, B6→A2Kb not shown) , whilst LMP2-specific T cells displayed no antigen-specific functions (Fig 5B and C) . These data indicated that the phenotypic differences between WT1-specific and LMP2-specific T cells correlated with the ability of WT1-specific T cells to display antigen-specific effector function without prior vaccination. (Fig 6A and B) . In transiently lymphopenic hosts, the WT1-specific T cells converted more efficiently into memory phenotype cells than the WT1-TCR negative control T cells expressing endogenous TCRs (Fig 6B left panel) . Cytotoxicity experiments in the secondary hosts demonstrated efficient WT1-specific effector function, which correlated with robust WT1-specific proliferation ex-vivo (Fig 6C) . This clearly demonstrated that the CD44 high /CD62L high memory phenotype T cells were capable of displaying antigen-specific effector function without prior vaccination.
For
WT1-specific T cells accumulate in the bone marrow without impairing stem cell function.
Considering that bone marrow resident stem/progenitor cells express low levels of WT1 we explored whether WT1-specific T cells accumulated in the bone marrow of mice transplanted with A2Kb stem cells. Analysis of the donor T cell compartment showed an increased percentage of WT1-specific T cells in the bone marrow compared to lymph nodes and spleen (Fig 7A) . In contrast, analysis of LMP2-TCR transplanted mice demonstrated no enrichment of LMP2-specific T cells in the bone marrow compared to lymph nodes and spleen of these mice (Fig 7A) . It was possible that the accumulation of WT1-specific T cells was due to selective recruitment and proliferation of memory phenotype T cells to the bone marrow, as shown in other studies (33).
However, analysis of WT1-specific T cells showed that the relative frequency of naïve and memory phenotype cells was similar in bone marrow compared to spleen and lymph nodes (data not shown). This suggests that the observed accumulation in bone marrow of WT1-specific T cells, but not LMP2-specific T cells, was primarily driven by the specificity and not the memory phenotype of WT1-T cells.
Finally, we examined whether the presence of WT1-specific T cells resulted in damage to the stem/progenitor cells in the bone marrow of transplanted mice. Bone marrow was harvested from WT1-TCR transplanted mice and from control mice, followed by transplantation into myeloablated secondary recipients to measure long-term reconstitution of haematopoiesis. Analysis revealed that both myeloid and lymphoid lineages were efficiently reconstituted by bone marrow isolated from donors transplanted with WT1-TCR transduced stem cells, demonstrating that WT1-specific T cells did not impair the functional competence of the haematopoietic progenitor/stem cells (Fig 7B) .
However, T cell engraftment was slower in the experimental mice compared to control mice (p<0.01). It is possible that lentiviral vector driven TCR expression in developing thymocytes alters the kinetics of T cell repertoire selection and T cell reconstitution in the thymus of transplanted mice.
For The WT1-specific TCR used was derived from high avidity human allo-restricted CD8+ T cells that efficiently recognise WT1-expressing human leukemia cells without impairing the function of human haematopoietic stem/progenitor cells (20) . In this study the TCR was not deleted in the thymus but successfully selected into the single-positive CD8 lineage. Although some studies have demonstrated thymic WT1 expression, we found that the expression was high in the mesothelial lining but not in the epithelial stroma of the thymus, in agreement with previously described WT1 expression in cells with dual mesenchymal and epithelial properties such as mesothelium, renal podocytes and testicular Sertoli cells (35). Our data indicate that physiological WT1 expression does not prevent selection of a high-avidity WT1-specific human TCR.
Unexpectedly, in our study WT1-specific T cells did not display signs of self-antigen induced tolerance, but instead differentiated spontaneously into fully functional memory phenotype T cells.
Previous studies have clearly demonstrated that lymphopenia induced proliferation can result in the differentiation of naïve T cells into memory phenotype T cells (36, 37) and such cells can display antigen-specific effector function. However, this effect was transient, as antigen-specific effector function was only detectable during a time period of 12 to 31 days after T cell transfer into lymphopenic hosts (37). Although there are some similarities between our model and lymphopenia induced memory phenotype induction, there are also important differences. In our stem cell transplantation model, thymic development generates a polyclonal T cell population that reconstitutes the peripheral compartment. In this situation, the majority of non-WT1-specific T cells do not develop a memory phenotype, while a large proportion of the WT1-specifc T cells differentiate into memory T cells that maintain the ability to display antigen-specific effector function for several months after the initial stem cell transplantation. The reconstitution of a lymphopenic periphery following stem cell transplantation is similar to the generation of a peripheral T cell repertoire in newborn mice, where adoptive T cell transfer has previously demonstrated that lymophopenia induced proliferation promoted memory phenotype development in approximately 20% of a transferred polyclonal T cell population (38). It was also shown that two mono-specific TCR transgenic T cell populations did not proliferate in the newborn hosts, suggesting that these TCRs, like the TCRs of 80% of the polyclonal T cells, were not stimulated sufficiently by endogenous MHC/peptide ligands to trigger proliferation and memory development. These findings in neonates are very similar to our findings of T cell reconstitution after stem cell transplantation.
However, we found that the self-specific WT1-TCR was more effective than the polyclonal endogenous TCRs or the non-self-specific LMP2-TCR in differentiating into memory phenotype cells.
Our data is compatible with the proposal that chronic stimulation by self-antigen triggered the spontaneous differentiation of WT1-specific T cells into persisting memory cells. Unfortunately, both WT1 knockout mice as well as inducible tissue-specific knock out animals are not viable (39). Thus, it is not possible to perform stem cell transplantation experiments in a WT1-deficient host to unequivocally prove that WT1 is the self-antigen driving the generation of central memory T cells.
Although specificity for self-antigen has been suggested to play a role in the generation of natural central memory phenotype cells, experimental evidence to support this has not yet been described (22) . A population of memory phenotype T cells was found in germ free mice, suggesting that exposure to microbial antigens is not essential for their development (23, 40). Typically, the number of natural memory phenotype T cells increase with age (22) , which is similar to our observation that over time the frequency of WT1-specific T cells increased relative to the frequency
of WT1-negative T cells (data not shown). A recent report demonstrated that although natural memory phenotype T cells rapidly up-regulated CD69 upon encountering peptide antigen in vivo,
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From this did not correlate with in vivo cytokine production (23). The lack of detectable effector function led the authors to propose the term 'virtual memory cells'. In contrast, the WT1-specific T cells were not 'virtual memory cells' as they readily displayed in vivo cytotoxicity. A possible explanation for this difference is that cytotoxic effector function is more readily triggered than in vivo cytokine production. Alternatively, it is possible that the natural memory phenotype population contains less differentiated virtual memory cells as well as more differentiated T cells capable of full antigenspecific effector function. It is tempting to speculate that the generation of virtual memory T cells is primarily driven by homeostatic proliferation, as suggested by Haluszczak et al (23) 
